antiplatelets and ppis: controversies and choices of agents
DESCRIPTION
Antiplatelets and PPIs: Controversies and Choices of Agents. Thank you for taking the pre-assessment. To assess learning, these questions will be repeated at the end of the activity. Statin and Clopidogrel PK/PD Interaction Did Not Translate to Clinical Effect. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/1.jpg)
![Page 2: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/2.jpg)
![Page 3: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/3.jpg)
![Page 4: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/4.jpg)
![Page 5: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/5.jpg)
![Page 6: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/6.jpg)
![Page 7: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/7.jpg)
![Page 8: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/8.jpg)
![Page 9: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/9.jpg)
![Page 10: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/10.jpg)
![Page 11: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/11.jpg)
![Page 12: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/12.jpg)
![Page 13: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/13.jpg)
![Page 14: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/14.jpg)
![Page 15: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/15.jpg)
![Page 16: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/16.jpg)
![Page 17: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/17.jpg)
![Page 18: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/18.jpg)
![Page 19: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/19.jpg)
![Page 20: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/20.jpg)
![Page 21: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/21.jpg)
![Page 22: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/22.jpg)
![Page 23: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/23.jpg)
![Page 24: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/24.jpg)
![Page 25: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/25.jpg)
![Page 26: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/26.jpg)
![Page 27: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/27.jpg)
![Page 28: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/28.jpg)
![Page 29: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/29.jpg)
![Page 30: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/30.jpg)
![Page 31: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/31.jpg)
![Page 32: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/32.jpg)
![Page 33: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/33.jpg)
![Page 34: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/34.jpg)
![Page 35: Antiplatelets and PPIs: Controversies and Choices of Agents](https://reader035.vdocuments.us/reader035/viewer/2022062322/568144db550346895db1a7ab/html5/thumbnails/35.jpg)